Terms: = Colorectal cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Treatment
90 results:
1. Analysis of tumor microenvironment alterations in partially responsive rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Chen H; Zhang JH; Hao Q; Wu XL; Guo JX; Huang CX; Zhang J; Xing GS; An ZL; Ling Y; Zhao JG; Bao YN
Int J Colorectal Dis; 2024 Jun; 39(1):99. PubMed ID: 38926205
[TBL] [Abstract] [Full Text] [Related]
2. LINC00982-encoded protein PRDM16-DT regulates
Hu HF; Han L; Fu JY; He X; Tan JF; Chen QP; Han JR; He QY
Theranostics; 2024; 14(8):3317-3338. PubMed ID: 38855188
[TBL] [Abstract] [Full Text] [Related]
3. Multiomics-based molecular subtyping based on the commensal microbiome predicts molecular characteristics and the therapeutic response in breast cancer.
Qin W; Li J; Gao N; Kong X; Guo L; Chen Y; Huang L; Chen X; Qi F
Mol Cancer; 2024 May; 23(1):99. PubMed ID: 38730464
[TBL] [Abstract] [Full Text] [Related]
4. Location matters: spatial dynamics of tumor-infiltrating T cell subsets is prognostic in colon cancer.
Zhu H; Roelands J; Ahmed EI; Stouten I; Hoorntje R; van Vlierberghe RLP; Ijsselsteijn ME; Lei X; de Miranda NFCC; Tollenaar RAEM; Vahrmeijer AL; Bedognetti D; Hendrickx WRL; Kuppen PJK
Front Immunol; 2024; 15():1293618. PubMed ID: 38375478
[TBL] [Abstract] [Full Text] [Related]
5. FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer.
Li H; Zheng N; Guo A; Tang W; Li M; Cao Y; Ma X; Cao H; Ma Y; Wang H; Zhao S
Cell Death Dis; 2024 Feb; 15(2):107. PubMed ID: 38302412
[TBL] [Abstract] [Full Text] [Related]
6. Integrin-linked kinase expression in myeloid cells promotes colon tumorigenesis.
Ahmed AU; Almasabi S; Firestein R; Williams BRG
Front Immunol; 2023; 14():1270194. PubMed ID: 38077324
[TBL] [Abstract] [Full Text] [Related]
7. RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient colorectal cancer Treated with Regorafenib and Nivolumab.
Miao R; Kim DW; Yu J; Malafa M; Mehta R; Strosberg J; Imanirad I; Iyer S; Uhlik M; Benjamin L; Kim R
Oncology; 2024; 102(7):549-555. PubMed ID: 38061339
[TBL] [Abstract] [Full Text] [Related]
8. pH-Responsive Zinc Ion Regulating Immunomodulatory Nanoparticles for Effective cancer Immunotherapy.
Lim B; Kim KS; Na K
Biomacromolecules; 2023 Sep; 24(9):4263-4273. PubMed ID: 37616157
[TBL] [Abstract] [Full Text] [Related]
9. IMMUNOREACT 0: Biopsy-based immune biomarkers as predictors of response to neoadjuvant therapy for rectal cancer-A systematic review and meta-analysis.
Stepanyan A; Fassan M; Spolverato G; Castagliuolo I; Scarpa M; Scarpa M;
Cancer Med; 2023 Sep; 12(17):17878-17890. PubMed ID: 37537787
[TBL] [Abstract] [Full Text] [Related]
10. Immune microenvironment and lymph node yield in colorectal cancer.
Lee SH; Pankaj A; Neyaz A; Ono Y; Rickelt S; Ferrone C; Ting D; Patil DT; Yilmaz O; Berger D; Deshpande V; Yılmaz O
Br J Cancer; 2023 Oct; 129(6):917-924. PubMed ID: 37507544
[TBL] [Abstract] [Full Text] [Related]
11. Muscarinic Acetylcholine Receptor M3 Expression and Survival in Human colorectal Carcinoma-An Unexpected Correlation to Guide Future treatment?
Lobbes LA; Schütze MA; Droeser R; Arndt M; Pozios I; Lauscher JC; Hering NA; Weixler B
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175905
[TBL] [Abstract] [Full Text] [Related]
12. Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial.
Gögenur M; Balsevicius L; Bulut M; Colak N; Justesen TF; Fiehn AK; Jensen MB; Høst-Rasmussen K; Cappelen B; Gaggar S; Tajik A; Zahid JA; Bennedsen ALB; D'Ondes TDB; Raskov H; Sækmose SG; Hansen LB; Salanti A; Brix S; Gögenur I
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37172969
[TBL] [Abstract] [Full Text] [Related]
13. China special issue on gastrointestinal tumors-Regulatory-immunoscore-A novel indicator to guide precision adjuvant chemotherapy in colorectal cancer.
Fang L; Yao Y; Guan X; Liao Y; Wang B; Cui L; Han S; Zou H; Su D; Ma Y; Liu B; Wang Y; Huang R; Ruan Y; Yu X; Yao Y; Liu C; Zhang Y
Int J Cancer; 2023 Dec; 153(11):1904-1915. PubMed ID: 37085990
[TBL] [Abstract] [Full Text] [Related]
14. Vascular endothelial growth factor inhibitors promote antitumor responses via tumor microenvironment immunosuppression in advanced colorectal cancer.
Hamada Y; Tanoue K; Kita Y; Tanabe K; Hokonohara K; Wada M; Hozaka Y; Oi H; Nakayama C; Higashi M; Arigami T; Mori S; Ohtsuka T
Scand J Gastroenterol; 2023; 58(9):1009-1020. PubMed ID: 36987919
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study.
Cho H; Kim JE; Hong YS; Kim SY; Kim J; Ryu YM; Kim SY; Kim TW
Oncoimmunology; 2022; 11(1):2148374. PubMed ID: 36451674
[TBL] [Abstract] [Full Text] [Related]
16. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
[TBL] [Abstract] [Full Text] [Related]
17. A study on the correlation between M2 macrophages and regulatory T cells in the progression of colorectal cancer.
Chen Y; Gao Y; Ma X; Wang Y; Liu J; Yang C; Wang Y; Bao C; Song X; Feng Y; Sun Y; Qiao S
Int J Biol Markers; 2022 Dec; 37(4):412-420. PubMed ID: 36285512
[TBL] [Abstract] [Full Text] [Related]
18. The immune microenvironment landscape shows treatment-specific differences in rectal cancer patients.
Graham Martínez C; Barella Y; Kus Öztürk S; Ansems M; Gorris MAJ; van Vliet S; Marijnen CAM; Nagtegaal ID
Front Immunol; 2022; 13():1011498. PubMed ID: 36238289
[TBL] [Abstract] [Full Text] [Related]
19. GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient colorectal Carcinoma Tumor-Derived T Cells.
Rakké YS; Campos Carrascosa L; van Beek AA; de Ruiter V; van Gemerden RS; Doukas M; Doornebosch PG; Vermaas M; Ter Borg S; van der Harst E; Coene PPLO; Kliffen M; Grünhagen DJ; Verhoef C; IJzermans JNM; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2023; 15(1):77-97. PubMed ID: 36155259
[TBL] [Abstract] [Full Text] [Related]
20. Immune Evasion and Drug Resistance Mediated by USP22 in cancer: Novel Targets and Mechanisms.
Guo J; Zhao J; Fu W; Xu Q; Huang D
Front Immunol; 2022; 13():918314. PubMed ID: 35935969
[TBL] [Abstract] [Full Text] [Related]
[Next]
